Novel strategies for the preventionand treatment of Candida infections: The potential of immunotherapy

FEMS Microbiology Reviews

Volumn 34, Issue 6, 2010, Pages 1063-1075

  van de Veerdonk, Frank L ^a   Netea, Mihai G ^a   Joosten, Leo A ^a   van der Meer, Jos W M ^a   Kullberg, Bart Jan ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Candida; Immunotherapy; Infections; Treatment

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; EFUNGUMAB; FLUCONAZOLE; FUNGUS VACCINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; PLACEBO; RECOMBINANT ANTIBODY; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT MANNAN HUMAN ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VORICONAZOLE; YEAST KILLER FACTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANAPHYLAXIS; ANTIFUNGAL SUSCEPTIBILITY; ANTIGEN PRESENTATION; ASPERGILLOSIS; CANDIDEMIA; CANDIDIASIS; CHRONIC GRANULOMATOUS DISEASE; CLINICAL TRIAL; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; FUNGUS GROWTH; GASTROINTESTINAL CANDIDIASIS; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; IMMUNOMODULATION; IMMUNOTHERAPY; INNATE IMMUNITY; INTENSIVE CARE UNIT; INVASIVE CANDIDIASIS; LUNG INJURY; MICROBIOLOGICAL EXAMINATION; MUCOCUTANEOUS CANDIDIASIS; NONHUMAN; ONYCHOMYCOSIS; OROPHARYNX CANDIDIASIS; OUTCOME ASSESSMENT; PATHOGENESIS; PHAGOCYTOSIS; REINFECTION; REVIEW; STEM CELL TRANSPLANTATION; TH17 CELL; VAGINA CANDIDIASIS; CANDIDA; IMMUNOLOGY; MICROBIOLOGY; PHYSIOLOGY;

CANDIDA;

CANDIDA; CANDIDIASIS; HUMANS; IMMUNOTHERAPY;

EID: 78649391120     PISSN: 01686445     EISSN: 15746976     Source Type: Journal    
DOI: 10.1111/j.1574-6976.2010.00232.x     Document Type: Review

References (143)

1. Ahonen P, Myllarniemi S, Sipila I & Perheentupa J (1990) Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. New Engl J Med 322: 1829-1836.
2. Babula O, Lazdane G, Kroica J, Ledger WJ & Witkin SS (2003) Relation between recurrent vulvovaginal candidiasis, vaginal concentrations of mannose-binding lectin, and a mannose-binding lectin gene polymorphism in Latvian women. Clin Infect Dis 37: 733-737.
3. Babula O, Lazdane G, Kroica J, Linhares IM, Ledger WJ & Witkin SS (2005) Frequency of interleukin-4 (IL-4) - 589 gene polymorphism and vaginal concentrations of IL-4, nitric oxide, and mannose-binding lectin in women with recurrent vulvovaginal candidiasis. Clin Infect Dis 40: 1258-1262.
4. Bacci A, Montagnoli C, Perruccio K et al. (2002) Dendritic cells pulsed with fungal RNA induce protective immunity to Candida albicans in hematopoetic transplantation. J Immunol 168: 2904-2913.
5. Balish E, Wagner RD, Vasquez-Torres A, Pierson C & Warner T (1998) Candidiasis in interferon-gamma knock-out (IFN-gamma - / -) mice. J Infect Dis 178: 478-487.
6. Baltch AL, Bopp LH, Smith RP, Ritz WJ, Carlyn CJ & Michelsen PB (2005) Effects of voriconazole, granulocyte-macrophage colony-stimulating factor, and interferon gamma on intracellular fluconazole-resistant Candida glabrata and Candida krusei in human monocyte-derived macrophages. Diagn Micr Infec Dis 52: 299-304.
7. Baltch AL, Bopp LH, Smith RP, Ritz WJ & Michelsen PB (2008) Anticandidal effects of voriconazole and caspofungin, singly and in combination, against Candida glabrata, extracellularly and intracellularly in granulocyte-macrophage colony stimulating factor (GM-CSF)-activated human monocytes. J Antimicrob Chemoth 62: 1285-1290.
8. Bistoni F, Vecchiarelli A, Cenci E, Puccetti P, Marconi P & Cassone A (1986) Evidence for macrophage-mediated protection against lethal Candida albicans infection. Infect Immun 51: 668-674.
9. Black CA, Eyers FM, Russell A, Dunkley ML, Clancy RL & Beagley KW (1998) Acute neutropenia decreases inflammation associated with murine vaginal candidiasis but has no effect on the course of infection. Infect Immun 66: 1273-1275.
10. Bodasing N, Seaton RA, Shankland GS & Pithie A (2002) Gamma-interferon treatment for resistant oropharyngeal candidiasis in an HIV-positive patient. J Antimicrob Chemoth 50: 765-766.
11. Bozza S, Perruccio K, Montagnoli C et al. (2003) A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation. Blood 102: 3807-3814.
12. Bozza S, Montagnoli C, Gaziano R, Rossi G, Nkwanyuo G, Bellocchio S & Romani L (2004) Dendritic cell-based vaccination against opportunistic fungi. Vaccine 22: 857-864.
13. Brach MA, de Vos S, Gruss HJ & Herrmann F (1992) Prolongation of survival of human polymorphonuclear neutrophils by granulocyte-macrophage colony-stimulating factor is caused by inhibition of programmed cell death. Blood 80: 2920-2924.
14. Brummer E & Stevens DA (1987) Activation of pulmonary macrophages for fungicidal activity by gamma-interferon or lymphokines. Clin Exp Immunol 70: 520-528.
15. Brummer E & Stevens DA (1989) Candidacidal mechanisms of peritoneal macrophages activated with lymphokines or g-interferon. J Med Microbiol 28: 173-181.
16. Brummer E, Morrison CJ & Stevens DA (1985) Recombinant and natural gamma-interferon activation of macrophages in vitro: different dosage requirements for induction of killing activity against phagocytizable and nonphagocytizable fungi. Infect Immun 49: 724-730.
17. Brummer E, Hanson LH & Stevens DA (1991) Kinetics and requirements for activation of macrophages for fungicidal activity - effect of protein synthesis inhibitors and immunosuppressants on activation and fungicidal mechanism. Cell Immunol 132: 236-245.
18. Brunetti L, De Caro F, Boccia G, Cavallo P & Capunzo M (2008) Surveillance of nosocomial infections: a preliminary study on yeast carriage on hands of healthcare workers. J Prev Med Hyg 49: 63-68.
19. Cassone A, De Bernardis F & Santoni G (2007) Anticandidal immunity and vaginitis: novel opportunities for immune intervention. Infect Immun 75: 4675-4686.
20. Clemons KV & Stevens DA (2000) Treatment of orogastrointestinal candidosis in SCID mice with fluconazole alone or in combination with recombinant granulocyte colony-stimulating factor or interferon-gamma. Med Mycol 38: 213-219.
21. Conti HR, Shen F, Nayyar N et al. (2009) Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med 206: 299-311.
22. Cutler JE (2001) N-glycosylation of yeast, with emphasis on Candida albicans. Med Mycol 39S: 75-86.
23. Davis SD, Schaller J & Wedgwood RJ (1966) Job's Syndrome. Recurrent, 'cold', staphylococcal abscesses. Lancet 1: 1013-1015.
24. de Repentigny L, Lewandowski D & Jolicoeur P (2004) Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection. Clin Microbiol Rev 17: 729-759.
25. Dignani MC, Rex JH, Chan KW et al. (2005) Immunomodulation with interferon-gamma and colony-stimulating factors for refractory fungal infections in patients with leukemia. Cancer 104: 199-204.
26. Djeu JY, Blanchard DK, Halkias D & Friedman H (1986) Growth inhibition of Candida albicans by human polymorphonuclear neutrophils: activation by interferon-g and tumor necrosis factor. J Immunol 137: 2980-2984.
27. Dongari-Bagtzoglou A & Fidel PL Jr (2005) The host cytokine responses and protective immunity in oropharyngeal candidiasis. J Dent Res 84: 966-977.
28. Dongari-Bagtzoglou A & Kashleva H (2003) Candida albicans triggers interleukin-8 secretion by oral epithelial cells. Microb Pathogenesis 34: 169-177.
29. Dongari-Bagtzoglou A, Villar CC & Kashleva H (2005) Candida albicans-infected oral epithelial cells augment the anti-fungal activity of human neutrophils in vitro. Med Mycol 43: 545-549.
30. Eckert LO (2006) Clinical practice. Acute vulvovaginitis. New Engl J Med 355: 1244-1252.
31. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS & Flavell RA (2008) Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453: 1122-1126.
32. Ellepola AN & Morrison CJ (2005) Laboratory diagnosis of invasive candidiasis. J Microbiol 43 (spec no.): 65-84.
33. Ellis M, Al-Ramadi B, Bernsen R, Kristensen J, Alizadeh H & Hedstrom U (2009) Prospective evaluation of mannan and anti-mannan antibodies for diagnosis of invasive Candida infections in patients with neutropenic fever. J Med Microbiol 58: 606-615.
34. Ernst JF & Prill SK (2001) O-glycosylation. Med Mycol 39 (suppl 1): 67-74.
35. Eyerich K, Foerster S, Rombold S et al. (2008) Patients with chronic mucocutaneous candidiasis exhibit reduced production of Th17-associated cytokines IL-17 and IL-22. J Invest Dermatol 128: 2640-2645.
36. Ferwerda B, Ferwerda G, Plantinga TS et al. (2009) Human dectin-1 deficiency and mucocutaneous fungal infections. New Engl J Med 361: 1760-1767.
37. Fidel PL Jr, Barousse M, Espinosa T et al. (2004) An intravaginal live Candida challenge in humans leads to new hypotheses for the immunopathogenesis of vulvovaginal candidiasis. Infect Immun 72: 2939-2946.
38. Gadish M, Kletter Y, Flidel O, Nagler A, Slavin S & Fabian I (1991) Effects of recombinant human granulocyte and granulocyte-macrophage colony-stimulating factors on neutrophil function following autologous bone marrow transplantation. Leukocyte Res 15: 1175-1182.
39. Gallin JI, Malech HL & Melnick DA and the International Chronic Granulomatous Disease Cooperative Study Group (1991) A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. New Engl J Med 324: 509-516.
40. Gallin JI, Farber JM, Holland SM & Nutman TB (1995) Interferon-gamma in the management of infectious diseases. Ann Intern Med 123: 216-222.
41. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS & Bearden DT (2006) Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 43: 25-31.
42. Gaviria JM, van Burik JA, Dale DC, Root RK & Liles WC (1999) Modulation of neutrophil-mediated activity against the pseudohyphal form of Candida albicans by granulocyte colony-stimulating factor (G-CSF) administered in vivo. J Infect Dis 179: 1301-1304.
43. Giraldo PC, Babula O, Goncalves AK, Linhares IM, Amaral RL, Ledger WJ & Witkin SS (2007) Mannose-binding lectin gene polymorphism, vulvovaginal candidiasis, and bacterial vaginosis. Obstet Gynecol 109: 1123-1128.
44. Glocker EO, Hennigs A, Nabavi M et al. (2009) A homozygous CARD9 mutation in a family with susceptibility to fungal infections. New Engl J Med 361: 1727-1735.
45. Gow NAR, Netea MG, Munro CA et al. (2007) Recognition of Candida albicans b-glucan by dectin-1 induces cytokines and has non-redundant effects on the activation of innate immunity. J Infect Dis 196: 1565-1571.
46. Graybill JR, Bocanegra R & Luther M (1995) Antifungal combination therapy with granulocyte colony-stimulating factor and fluconazole in experimental disseminated candidiasis. Eur J Clin Microbiol 14: 700-703.
47. Grimbacher B, Holland SM, Gallin JI et al. (1999) Hyper-IgE syndrome with recurrent infections - an autosomal dominant multisystem disorder. New Engl J Med 340: 692-702.
48. Gudlaugsson O, Gillespie S, Lee K et al. (2003) Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 37: 1172-1177.
49. Guery BP, Arendrup MC, Auzinger G et al. (2009) Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: part II. Treatment. Intens Care Med 35: 206-214.
50. Han Y & Cutler JE (1995) Antibody response that protects against disseminated candidiasis. Infect Immun 63: 2714-2719.
51. Han Y, Ulrich MA & Cutler JE (1999) Candida albicans mannan extract-protein conjugates induce a protective immune response against experimental candidiasis. J Infect Dis 179: 1477-1484.
52. Han Y, Riesselman MH & Cutler JE (2000) Protection against candidiasis by an immunoglobulin G3 (IgG3) monoclonal antibody specific for the same mannotriose as an IgM protective antibody. Infect Immun 68: 1649-1654.
53. Herbrecht R, Fohrer C & Nivoix Y (2006) Mycograb for the treatment of invasive candidiasis. Clin Infect Dis 43: 1083; author reply 1083-1084.
54. Hernandez-Castro R, Arroyo-Escalante S, Carrillo-Casas EM et al. (2009) Outbreak of Candida parapsilosis in a neonatal intensive care unit: a health care workers source. Eur J Pediatr [Epub ahead of print].
55. Hodgetts S, Nooney L, Al-Akeel R, Curry A, Awad S, Matthews R & Burnie J (2008) Efungumab and caspofungin: pre-clinical data supporting synergy. J Antimicrob Chemoth 61: 1132-1139.
56. Huang W, Na L, Fidel PL & Schwarzenberger P (2004) Requirement for interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis 190: 524-631.
57. Huang YC, Lin TY, Leu HS, Peng HL, Wu JH & Chang HY (1999) Outbreak of Candida parapsilosis fungemia in neonatal intensive care units: clinical implications and genotyping analysis. Infection 27: 97-102.
58. Hubel K, Dale DC & Liles WC (2002) Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interferon-gamma. J Infect Dis 185: 1490-1501.
59. Ibrahim AS, Spellberg BJ, Avenissian V, Fu Y, Filler SG & Edwards JE Jr (2005) Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity. Infect Immun 73: 999-1005.
60. Ibrahim AS, Spellberg BJ, Avanesian V, Fu Y & Edwards JE Jr (2006) The anti-Candida vaccine based on the recombinant N-terminal domain of Als1p is broadly active against disseminated candidiasis. Infect Immun 74: 3039-3041.
61. Iorio E, Torosantucci A, Bromuro C et al. (2008) Candida albicans cell wall comprises a branched beta-D-(1- > 6)-glucan with beta-D-(1- > 3)-side chains. Carbohyd Res 343: 1050-1061.
62. Kaposzta R, Tree P, Marodi L & Gordon S (1998) Characteristics of invasive candidiasis in gamma interferon-and interleukin-4-deficient mice: role of macrophages in host defense against Candida albicans. Infect Immun 66: 1708-1717.
63. Kedzierska A, Kochan P, Pietrzyk A & Kedzierska J (2007) Current status of fungal cell wall components in the immunodiagnostics of invasive fungal infections in humans: galactomannan, mannan and (1-4 3)-beta-D-glucan antigens. Eur J Clin Microbiol 26: 755-766.
64. Kirkpatrick CH (2001) Chronic mucocutaneous candidiasis. Pediatr Infect Dis J 20: 197-206.
65. Kullberg BJ, Van 't Wout JW, Hoogstraten C & Van Furth R (1993) Recombinant interferon-g enhances resistance to acute disseminated Candida albicans infection in mice. J Infect Dis 168: 436-443.
66. Kullberg BJ, Netea MG, Curfs JH, Keuter M, Meis JF & van der Meer JW (1998) Recombinant murine granulocyte colony-stimulating factor protects against acute disseminated Candida albicans infection in nonneutropenic mice. J Infect Dis 177: 175-181.
67. Kullberg BJ, Netea MG, Vonk AG & van der Meer JW (1999) Modulation of neutrophil function in host defense against disseminated Candida albicans infection in mice. FEMS Immunol Med Mic 26: 299-307.
68. Kullberg BJ, Oude Lashof AM & Netea MG (2004) Design of efficacy trials of cytokines in combination with antifungal drugs. Clin Infect Dis 39 (suppl 4): S218-S223.
69. Lau A, Halliday C, Chen SC, Playford EG, Stanley K & Sorrell TC (2009) Comparison of whole blood, serum and plasma for early detection of Candidemia by multiplex-tandem PCR. J Clin Microbiol 48: 811-816.
70. Lavigne LM, Schopf LR, Chung CL, Maylor R & Sypek JP (1998) The role of recombinant IL-12 and IFN-gamma in the pathogenesis of a murine Candida albicans infection. J Immunol 160: 284-292.
71. Lechner AJ, Lamprech KE, Potthoff LH, Tredway TL & Matuschak GM (1994) Recombinant GM-CSF reduces lung injury and mortality during neutropenic Candida sepsis. Am J Physiol 266: L561-L568.
72. Leibundgut-Landmann S, Osorio F, Brown GD & Reis e Sousa C (2008) Stimulation of dendritic cells via the dectin-1/Syk pathway allows priming of cytotoxic T-cell responses. Blood 112: 4971-4980.
73. Leon C, Ruiz-Santana S, Saavedra P et al. (2006) A bedside scoring system ('Candida score') for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 34: 730-737.
74. Levy DA, Bohbot JM, Catalan F, Normier G, Pinel AM & Dussourd d'Hinterland L (1989) Phase II study of D.651, an oral vaccine designed to prevent recurrences of vulvovaginal candidiasis. Vaccine 7: 337-340.
75. Li L & Dongari-Bagtzoglou A (2009) Epithelial GM-CSF induction by Candida glabrata. J Dent Res 88: 746-751.
76. Lilic D (2002) New perspectives on the immunology of chronic mucocutaneous candidiasis. Curr Opin Infect Dis 15: 143-147.
77. Lin L, Ibrahim AS, Xu X et al. (2009) Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog 5: e1000703.
78. Liu F, Liao Q & Liu Z (2006) Mannose-binding lectin and vulvovaginal candidiasis. Int J Gynecol Obstet 92: 43-47.
79. Lupetti A, Tavanti A, Davini P et al. (2002) Horizontal transmission of Candida parapsilosis candidemia in a neonatal intensive care unit. J Clin Microbiol 40: 2363-2369.
80. Marcil A, Harcus D, Thomas DY & Whiteway M (2002) Candida albicans killing by RAW 264.7 mouse macrophage cells: effects of Candida genotype, infection ratios, and gamma interferon treatment. Infect Immun 70: 6319-6329.
81. Marodi L, Schreiber S, Anderson DC, MacDermott RP, Korchak HM & Johnston RB Jr (1993) Enhancement of macrophage Candidacidal activity by interferon-g. Increased phagocytosis, killing, and calcium signal mediated by a decreased number of mannose receptors. J Clin Invest 91: 2596-2601.
82. Marquis M, Lewandowski D, Dugas V et al. (2006) CD8+ T cells but not polymorphonuclear leukocytes are required to limit chronic oral carriage of Candida albicans in transgenic mice expressing human immunodeficiency virus type 1. Infect Immun 74: 2382-2391.
83. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR & Mitchell TC (2007) The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316: 1628-1632.
84. Matthews RC (1992) The 14th C. L. Oakley Lecture. Candida albicans HSP 90: link between protective and auto immunity. J Med Microbiol 36: 367-370.
85. Matthews RC (1994) Pathogenicity determinants of Candida albicans: potential targets for immunotherapy? Microbiology 140: 1505-1511
86. McCluskie MJ & Krieg AM (2006) Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA. Curr Top Microbiol 311: 155-178.
87. Milner JD, Brenchley JM, Laurence A et al. (2008) Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 452: 773-776.
88. Minegishi Y, Saito M, Tsuchiya S et al. (2007) Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 448: 1058-1062.
89. Miossec P, Korn T & Kuchroo VK (2009) Interleukin-17 and type 17 helper T cells. New Engl J Med 361: 888-898.
90. Mostefaoui Y, Bart C, Frenette M & Rouabhia M (2004) Candida albicans and Streptococcus salivarius modulate IL-6, IL-8, and TNF-alpha expression and secretion by engineered human oral mucosa cells. Cell Microbiol 6: 1085-1096.
91. Murciano C, Yanez A, Gil ML & Gozalbo D (2007) Both viable and killed Candida albicans cells induce in vitro production of TNF-alpha and IFN-gamma in murine cells through a TLR2-dependent signalling. Eur Cytokine Netw 18: 38-43.
92. Myers TA, Leigh JE, Arribas AR, Hager S, Clark R, Lilly E & Fidel PL Jr (2003) Immunohistochemical evaluation of T cells in oral lesions from human immunodeficiency virus-positive persons with oropharyngeal candidiasis. Infect Immun 71: 956-963.
93. Netea MG, de Graaf C, Vonk A, Verschueren I, Van der Meer JWM & Kullberg BJ (2002) The role of Toll-like receptors in the defense against disseminated candidiasis. J Infect Dis 185: 1483-1489.
94. Netea MG, Vonk AG, van den Hoven M et al. (2003) Differential role of IL-18 and IL-12 in the host defense against disseminated Candida albicans infection. Eur J Immunol 33: 3409-3417.
95. Netea MG, Gijzen K, Coolen N et al. (2004) Human dendritic cells are less potent at killing Candida albicans than both monocytes and macrophages. Microbes Infect 6: 985-989.
96. Netea MG, Gow NA, Munro CA et al. (2006) Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors. J Clin Invest 116: 1642-1650.
97. Netea MG, Brown GD, Kullberg BJ & Gow NA (2008) An integrated model of the recognition of Candida albicans by the innate immune system. Nat Rev Microbiol 6: 67-78.
98. Ohmit SE, Sobel JD, Schuman P, Duerr A, Mayer K, Rompalo A & Klein RS (2003) Longitudinal study of mucosal Candida species colonization and candidiasis among human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis 188: 118-127.
99. Ostrosky-Zeichner L, Sable C, Sobel J et al. (2007) Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol 26: 271-276.
100. Pachl J, Svoboda P, Jacobs F et al. (2006) A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 42: 1404-1413.
101. Pappas PG, Kauffman CA, Andes D et al. (2009) Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48: 503-535.
102. Pfaller MA & Diekema DJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20: 133-163.
103. Pietrella D, Rachini A, Torosantucci A et al. (2010) A beta-glucan-conjugate vaccine and anti-beta-glucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique. Vaccine 28: 1717-1725.
104. Pivarcsi A, Bodai L, Rethi B et al. (2003) Expression and function of Toll-like receptors 2 and 4 in human keratinocytes. Int Immunol 15: 721-730.
105. Polonelli L, Lorenzini R, De Bernardis F et al. (1993) Idiotypic vaccination: immunoprotection mediated by anti-idiotypic antibodies with antibiotic activity. Scand J Immunol 37: 105-110.
106. Polonelli L, De Bernardis F, Conti S et al. (1994) Idiotypic intravaginal vaccination to protect against Candidal vaginitis by secretory, yeast killer toxin-like anti-idiotypic antibodies. J Immunol 152: 3175-3182.
107. Powderly WG, Gallant JE, Ghannoum MA, Mayer KH, Navarro EE & Perfect JR (1999) Oropharyngeal candidiasis in patients with HIV: suggested guidelines for therapy. AIDS Res Hum Retrov 15: 1619-1623.
108. Prella M, Bille J, Pugnale M, Duvoisin B, Cavassini M, Calandra T & Marchetti O (2005) Early diagnosis of invasive candidiasis with mannan antigenemia and antimannan antibodies. Diagn Micr Infec Dis 51: 95-101.
109. Redmond HP, Shou J, Gallagher HJ, Kelly CJ & Daly JM (1993) Macrophage-dependent Candidacidal mechanisms in the murine system. Comparison of murine Kupffer cell and peritoneal macrophage Candidacidal mechanisms. J Immunol 150: 3427-3433.
110. Richardson MD, Brownlie CE & Shankland GS (1992) Enhanced phagocytosis and intracellular killing of Candida albicans by GM-CSF-activated human neutrophils. J Med Vet Mycol 30: 433-441.
111. Richet HM, Andremont A, Tancrede C, Pico JL & Jarvis WR (1991) Risk factors for candidemia in patients with acute lymphocytic leukemia. Rev Infect Dis 13: 211-215.
112. Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ & Pfaller MA (2005) Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol 43: 2155-2162.
113. Robinson MJ, Osorio F, Rosas M et al. (2009) Dectin-2 is a Syk-coupled pattern recognition receptor crucial for Th17 responses to fungal infection. J Exp Med 206: 2037-2051.
114. Roilides E, Holmes A, Blake C, Pizzo PA & Walsh TJ (1995) Effects of granulocyte colony-stimulating factor and interferon-gamma on antifungal activity of human polymorphonuclear neutrophils against pseudohyphae of different medically important Candida species. J Leukocyte Biol 57: 651-656.
115. Rokusz L, Liptay L & Kadar K (2001) Successful treatment of chronic disseminated candidiasis with fluconazole and a granulocyte-macrophage colony-stimulating factor combination. Scand J Infect Dis 33: 784-786.
116. Samonis G & Bafaloukos D (1992) Fungal infections in cancer patients: an escalating problem. In Vivo 6: 183-193.
117. Sangeorzan JA, Bradley SF, He X, Zarins LT, Ridenour GL, Tiballi RN & Kauffman CA (1994) Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 97: 339-346.
118. Shahar E, Krivoy N & Pollack S (1999) Effective acute desensitization for immediate-type hypersensitivity to human granulocyte-monocyte colony stimulating factor. Ann Allerg Asthma Im 83: 543-546.
119. Sobel JD (2007) Vulvovaginal candidosis. Lancet 369: 1961-1971.
120. Sobel JD, Faro S, Force RW et al. (1998) Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 178: 203-211.
121. Sobel JD, Wiesenfeld HC, Martens M et al. (2004) Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New Engl J Med 351: 876-883.
122. Spellberg BJ, Ibrahim AS, Avenissian V, Filler SG, Myers CL, Fu Y & Edwards JE Jr (2005) The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice. Infect Immun 73: 6191-6193.
123. Spellberg BJ, Ibrahim AS, Avanesian V et al. (2006) Efficacyofthe anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis. J Infect Dis 194: 256-260.
124. Tobudic S, Kratzer C, Lassnigg A, Graninger W & Presterl E (2010) In vitro activity of antifungal combinations against Candida albicans biofilms. J Antimicrob Chemoth 65: 271-274.
125. Torosantucci A, Bromuro C, Chiani P et al. (2005)Anovelglyco-conjugate vaccine against fungal pathogens. J Exp Med 202: 597-606.
126. Tramsen L, Beck O, Schuster FR et al. (2007) Generation and characterization of anti-Candida T cells as potential immunotherapy in patients with Candida infection after allogeneic hematopoietic stem-cell transplant. J InfectDis196: 485-492.
127. Trinchieri G (1995) Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 13: 251-276.
128. van de Veerdonk FL, Kullberg BJ, van der Meer JW, Gow NA & Netea MG (2008) Host-microbe interactions: innate pattern recognition of fungal pathogens. Curr Opin Microbiol 11: 305-312.
129. van de Veerdonk FL, Marijnissen R, Joosten LA, Kullberg BJ, Drenth JP, Netea MG & van der Meer JW (2009a) Milder clinical hyperimmunoglobulin E syndrome phenotype is associated with partial interleukin-17 deficiency. Clin Exp Immunol 159: 57-64.
130. van de Veerdonk FL, Marijnissen RJ, Kullberg BJ et al. (2009b) The macrophage mannose receptor induces IL-17 in response to Candida albicans. Cell Host Microbe 5: 329-340.
131. van Eijk M, van Roomen CP, Renkema GH et al. (2005) Characterization of human phagocyte-derived chitotriosidase, a component of innate immunity. Int Immunol 17: 1505-1512.
132. Vazquez JA, Gupta S & Villanueva A (1998) Potential utility of recombinant human GM-CSF as adjunctive treatment of refractory oropharyngeal candidiasis in AIDS patients. Eur J Clin Microbiol 17: 781-783.
133. Vazquez JA, Hidalgo JA & De Bono S (2000) Use of sargramostim (rh-GM-CSF) as adjunctive treatment of fluconazole-refractory oropharyngeal candidiasis in patients with AIDS: a pilot study. HIV Clin Trials 1: 23-29.
134. Watson MC, Grimshaw JM, Bond CM, Mollison J & Ludbrook A (2002) Oral versus intra-vaginal imidazole and triazole anti-fungal agents for the treatment of uncomplicated vulvovaginal candidiasis (thrush): a systematic review. BJOG-Int J Obstet Gy 109: 85-95.
135. Weindl G, Naglik JR, Kaesler S, Biedermann T, Hube B, Korting HC & Schaller M (2007) Human epithelial cells establish direct antifungal defense through TLR4-mediated signaling. J Clin Invest 117: 3664-3672.
136. Wells CA, Salvage-Jones JA, Li X et al. (2008) The macrophage-inducible C-type lectin, mincle, is an essential component of the innate immune response to Candida albicans. J Immunol 180: 7404-7413.
137. Willment JA, Lin HH, Reid DM et al. (2003) Dectin-1 expression and function are enhanced on alternatively activated and GM-CSF-treated macrophages and are negatively regulated by IL-10, dexamethasone, and lipopolysaccharide. J Immunol 171: 4569-4573.
138. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP & Edmond MB (2004) Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39: 309-317.
139. Xin H, Dziadek S, Bundle DR & Cutler JE (2008) Synthetic glycopeptide vaccines combining beta-mannan and peptide epitopes induce protection against candidiasis. P Natl Acad Sci USA 105: 13526-13531.
140. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ & Feudtner C (2005) The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 41: 1232-1239.
141. Zaragoza R, Peman J, Quindos G et al. (2009) Clinical significance of the detection of Candida albicans germ tube-specific antibodies in critically ill patients. Clin Microbiol Infec 15: 592-595.
142. Zelante T, De Luca A, Bonifazi P et al. (2007) IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol 37: 2695-2706.
143. Zhang MX, Bohlman MC, Itatani C, Burton DR, Parren PW, St Jeor SC & Kozel TR (2006) Human recombinant antimannan immunoglobulin G1 antibody confers resistance to hematogenously disseminated candidiasis in mice. Infect Immun 74: 362-369.